Download full-text PDF |
Source |
---|
Zhonghua Er Ke Za Zhi
January 2025
Department of Medical Oncology, Pediatric Oncology Center,Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, National Key Clinical Discipline of Pediatric Oncology,Laboratory for Clinical Medicine, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing100045, China.
Zhonghua Bing Li Xue Za Zhi
June 2024
Department of Pathology, Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University), Nanjing 210029, China.
A 25-year-old male received palliative total gastrectomy plus D1 dissection plus Roux-en-Y reconstruction for hemorrhagic gastric cancer with left Virchow lymph node metastasis in 2013. The final diagnosis was Type 2, pT4a(se), pap>tub2 >hepatoid adenocarcinoma, pN3b, sM1, fStage Ⅳ. Because AFP was as high as 11,000 ng/mL, he was diagnosed with AFP-producing gastric cancer and started S-1 plus CDDP therapy.
View Article and Find Full Text PDFPathologie (Heidelb)
December 2023
Department of Morphological Sciences, Cordoba University Medical School, Avda. Menendez-Pidal S/N, 14004, Cordoba, Spain.
Germ cell tumors (GCTs) are now considered a curable cancer, with a > 95% cure rate in all patients and about 90% cure rate in patients with metastatic disease. The success of physicians in curing the disease is underpinned by multidisciplinary advances. Of relevance in this regard are the nowadays-applied homogeneous terminology based on pathologically better characterized testicular neoplasms and the development of a widely used risk stratification model for metastatic disease introduced by the International Germ Cell Cancer Collaborative Group in 1997 and updated in 2021.
View Article and Find Full Text PDFSci Rep
October 2023
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!